Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James J Harding

Showing results (121-130 of 138) with videos related to

Pageof 14
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2020
Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment SelectionWungki Park, Jiapeng Chen, Joanne F Chou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2022
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II TrialValentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2017
Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical PhenotypeMaeve A Lowery, Emmet J Jordan, Olca Basturk, et al.
Cancer Discovery|October 26, 2018
Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase InhibitionJames J Harding, Maeve A Lowery, Alan H Shih, et al.
JAMA Oncology|November 1, 2019
Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical TrialAndrea Cercek, Thomas Boerner, Benjamin R Tan, et al.
Cancer Immunology Research|January 7, 2026
IL-10R inhibition induces neutrophil tumoricidal activityDanny N Khalil, Ricardo Gomez, Amit Regev, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 30, 2025
Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 MutationsJames J Harding, Do-Youn Oh, Teresa Macarulla Mercade, et al.
Cancer Discovery|May 22, 2019
TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic CholangiocarcinomaLipika Goyal, Lei Shi, Leah Y Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2024
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket TrialPetros Grivas, Elena Garralda, Funda Meric-Bernstam, et al.
JCO Precision Oncology|September 12, 2017
OncoKB: A Precision Oncology Knowledge BaseDebyani Chakravarty, Jianjiong Gao, Sarah M Phillips, et al.
Pageof 14

Showing results (121-130 of 138) with videos related to

Sort By:
Pageof 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2020
Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment SelectionWungki Park, Jiapeng Chen, Joanne F Chou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2022
Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II TrialValentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 30, 2017
Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical PhenotypeMaeve A Lowery, Emmet J Jordan, Olca Basturk, et al.
Cancer Discovery|October 26, 2018
Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase InhibitionJames J Harding, Maeve A Lowery, Alan H Shih, et al.
JAMA Oncology|November 1, 2019
Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical TrialAndrea Cercek, Thomas Boerner, Benjamin R Tan, et al.
Cancer Immunology Research|January 7, 2026
IL-10R inhibition induces neutrophil tumoricidal activityDanny N Khalil, Ricardo Gomez, Amit Regev, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 30, 2025
Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 MutationsJames J Harding, Do-Youn Oh, Teresa Macarulla Mercade, et al.
Cancer Discovery|May 22, 2019
TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic CholangiocarcinomaLipika Goyal, Lei Shi, Leah Y Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2024
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket TrialPetros Grivas, Elena Garralda, Funda Meric-Bernstam, et al.
JCO Precision Oncology|September 12, 2017
OncoKB: A Precision Oncology Knowledge BaseDebyani Chakravarty, Jianjiong Gao, Sarah M Phillips, et al.
Pageof 14